145 related articles for article (PubMed ID: 37760629)
1. MRI Assessment of Changes in Tumor Vascularization during Neoadjuvant Anti-Angiogenic Treatment in Locally Advanced Breast Cancer Patients.
Mo T; Brandal SHB; Geier OM; Engebråten O; Nilsen LB; Kristensen VN; Hole KH; Hompland T; Fleischer T; Seierstad T
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760629
[TBL] [Abstract][Full Text] [Related]
2. A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers.
Baar J; Silverman P; Lyons J; Fu P; Abdul-Karim F; Ziats N; Wasman J; Hartman P; Jesberger J; Dumadag L; Hohler E; Leeming R; Shenk R; Chen H; McCrae K; Dowlati A; Remick SC; Overmoyer B
Clin Cancer Res; 2009 May; 15(10):3583-90. PubMed ID: 19417018
[TBL] [Abstract][Full Text] [Related]
3. Multiparametric characterization of response to anti-angiogenic therapy using USPIO contrast-enhanced MRI in combination with dynamic contrast-enhanced MRI.
Kim J; Kim E; Euceda LR; Meyer DE; Langseth K; Bathen TF; Moestue SA; Huuse EM
J Magn Reson Imaging; 2018 Jun; 47(6):1589-1600. PubMed ID: 29205621
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the changes induced by bevacizumab using a high temporal resolution DCE-MRI as prognostic factors for response to further neoadjuvant chemotherapy.
Etxano J; Insausti LP; Elizalde A; López Vega JM; Plazaola A; Martínez P
Acta Radiol; 2015 Nov; 56(11):1300-7. PubMed ID: 25348477
[TBL] [Abstract][Full Text] [Related]
5. Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts.
Moestue SA; Huuse EM; Lindholm EM; Bofin A; Engebraaten O; Mælandsmo GM; Akslen LA; Gribbestad IS
J Magn Reson Imaging; 2013 Nov; 38(5):1043-53. PubMed ID: 23908122
[TBL] [Abstract][Full Text] [Related]
6. Early Prediction of Breast Cancer Therapy Response using Multiresolution Fractal Analysis of DCE-MRI Parametric Maps.
Machireddy A; Thibault G; Tudorica A; Afzal A; Mishal M; Kemmer K; Naik A; Troxell M; Goranson E; Oh K; Roy N; Jafarian N; Holtorf M; Huang W; Song X
Tomography; 2019 Mar; 5(1):90-98. PubMed ID: 30854446
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response.
Yopp AC; Schwartz LH; Kemeny N; Gultekin DH; Gönen M; Bamboat Z; Shia J; Haviland D; D'Angelica MI; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR
Ann Surg Oncol; 2011 Aug; 18(8):2192-9. PubMed ID: 21286939
[TBL] [Abstract][Full Text] [Related]
8. A new algorithm for automatic vascular mapping of DCE-MRI of the breast: Clinical application of a potential new biomarker.
Vignati A; Giannini V; Carbonaro LA; Bertotto I; Martincich L; Sardanelli F; Regge D
Comput Methods Programs Biomed; 2014 Dec; 117(3):482-8. PubMed ID: 25262335
[TBL] [Abstract][Full Text] [Related]
9. PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
Rudin M; McSheehy PM; Allegrini PR; Rausch M; Baumann D; Becquet M; Brecht K; Brueggen J; Ferretti S; Schaeffer F; Schnell C; Wood J
NMR Biomed; 2005 Aug; 18(5):308-21. PubMed ID: 15918178
[TBL] [Abstract][Full Text] [Related]
10. Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy.
Drisis S; Metens T; Ignatiadis M; Stathopoulos K; Chao SL; Lemort M
Eur Radiol; 2016 May; 26(5):1474-84. PubMed ID: 26310583
[TBL] [Abstract][Full Text] [Related]
11. MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.
Jalali S; Chung C; Foltz W; Burrell K; Singh S; Hill R; Zadeh G
Neuro Oncol; 2014 Jun; 16(6):868-79. PubMed ID: 24759636
[TBL] [Abstract][Full Text] [Related]
12. Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: preliminary results.
Abramson RG; Li X; Hoyt TL; Su PF; Arlinghaus LR; Wilson KJ; Abramson VG; Chakravarthy AB; Yankeelov TE
Magn Reson Imaging; 2013 Nov; 31(9):1457-64. PubMed ID: 23954320
[TBL] [Abstract][Full Text] [Related]
13. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for pretreatment prediction of neoadjuvant chemotherapy response in locally advanced hypopharyngeal cancer.
Guo W; Zhang Y; Luo D; Yuan H
Br J Radiol; 2020 Nov; 93(1115):20200751. PubMed ID: 32915647
[No Abstract] [Full Text] [Related]
14. Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.
Partridge SC; Vanantwerp RK; Doot RK; Chai X; Kurland BF; Eby PR; Specht JM; Dunnwald LK; Schubert EK; Lehman CD; Mankoff DA
J Magn Reson Imaging; 2010 Nov; 32(5):1124-31. PubMed ID: 21031518
[TBL] [Abstract][Full Text] [Related]
15. Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy.
Hahn SY; Ko EY; Han BK; Shin JH; Ko ES
Eur J Radiol; 2014 Feb; 83(2):283-8. PubMed ID: 24315957
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer.
Wedam SB; Low JA; Yang SX; Chow CK; Choyke P; Danforth D; Hewitt SM; Berman A; Steinberg SM; Liewehr DJ; Plehn J; Doshi A; Thomasson D; McCarthy N; Koeppen H; Sherman M; Zujewski J; Camphausen K; Chen H; Swain SM
J Clin Oncol; 2006 Feb; 24(5):769-77. PubMed ID: 16391297
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic therapy affects the relationship between tumor vascular structure and function: A correlation study between micro-computed tomography angiography and dynamic contrast enhanced MRI.
Kim E; Kim J; Maelandsmo GM; Johansen B; Moestue SA
Magn Reson Med; 2017 Oct; 78(4):1513-1522. PubMed ID: 27888545
[TBL] [Abstract][Full Text] [Related]
18. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
[TBL] [Abstract][Full Text] [Related]
19. Effect of Neoadjuvant Chemotherapy on Angiogenesis and Cell Proliferation of Breast Cancer Evaluated by Dynamic Enhanced Magnetic Resonance Imaging.
Chang L; Lan H
Biomed Res Int; 2022; 2022():3156093. PubMed ID: 35915805
[TBL] [Abstract][Full Text] [Related]
20. Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer.
Røe K; Mikalsen LT; van der Kogel AJ; Bussink J; Lyng H; Ree AH; Marignol L; Olsen DR
Radiat Oncol; 2012 May; 7():75. PubMed ID: 22621752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
